Melanoma Dispatch
2.5K views | +0 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Combination Dabrafenib/Trametinib Increased PFS in BRAF-Positive Melanoma

Combination Dabrafenib/Trametinib Increased PFS in BRAF-Positive Melanoma | Melanoma Dispatch | Scoop.it

"Data from a phase 3 trial demonstrate combination dabrafenib and trametinib was superior to dabrafenib plus placebo for improved PFS in patients with BRAFV600-positive metastatic melanoma, according to data presented here at the ASCO Annual Meeting.


“ 'This is the first melanoma trial, phase 3, to have an active control arm,' researcher Georgina V. Long, BSc, PhD, MBBS, FRCP, oncologist at Melanoma Institute Australia at the University of Sydney, said of the COMBI-D trial."


Editor's note: This story describes the results of a clinical trial, in which volunteer patients are help test a new treatment. The treatment consists of a combination of the targeted therapy drugs dabrafenib and trametinib. Patients treated with the combination lived longer without progression of their cancer than patients who received dabrafenib plus a non-active placebo. Importantly, these results are specific to patients whose tumors have "BRAF V600E" mutations, which doctors can detect via molecular testing.

Cancer Commons's insight:

Healio  |  Jun 2, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Conference Abstract - MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients With Acquired Resistance to Combined RAF/MEK Inhibition

Conference Abstract - MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients With Acquired Resistance to Combined RAF/MEK Inhibition | Melanoma Dispatch | Scoop.it

"Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP–ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. This study represents an initial clinical genomic study of acquired resistance to combined RAF/MEK inhibition in BRAF-mutant melanoma, using WES and RNA-seq. The presence of diverse resistance mechanisms suggests that serial biopsies and genomic/molecular profiling at the time of resistance may ultimately improve the care of patients with resistant BRAF-mutant melanoma by specifying tailored targeted combinations to overcome specific resistance mechanisms."


Editor's note: We previously covered the benefits of a dabrafenib/trametinib combo for advanced-stage melanoma. However, some patients' tumors become resistant to this drug combination and new treatment routes need to be considered. This study is exploring how molecular testing of specific genetic mutations in patients' tumors might be used to help guide treatment decisions after they become resistant to the dabrafenib/trametinib combo.

Cancer Commons's insight:

MDLinx  |  Apr 8, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Immunotherapy, BRAF Inhibitor Sequence Affected Outcomes in Metastatic Melanoma

Immunotherapy, BRAF Inhibitor Sequence Affected Outcomes in Metastatic Melanoma | Melanoma Dispatch | Scoop.it

"Prior treatment with immunotherapy did not limit response to BRAF inhibitors among patients with metastatic melanoma, according to results of a retrospective study.


"However, patients who underwent initial treatment with BRAF inhibitors and subsequently received immunotherapy with ipilimumab (Yervoy, Bristol-Myers Squibb) demonstrated poorer outcomes, results showed.


"Patients with BRAF-positive metastatic melanoma have several treatment options, including BRAF inhibitors vemurafenib (Zelboraf, Hoffmann-La Roche) and dabrafenib  (Taflinar, GlaxoSmithKline), the MEK inhibitor trametinib (Mekinist, GlaxoSmithKline), and the immunotherapy agents ipilimumab and interleukin-2. Yet, there are limited data with regard to optimal sequencing, according to researchers."

Cancer Commons's insight:

Healio  |  Mar 14, 2014

more...
Krishan Maggon 's curator insight, March 15, 2014 4:19 AM

Prior treatment with BRAF inhibitors reduced subsequent response to immunotherapy. Prior treatment with ipilimumab had no effect on response to BRAF inhibitors.

Suggested by Cancer Commons
Scoop.it!

US FDA OKs Combo Treatment for Melanomas with BRAF Mutations

US FDA OKs Combo Treatment for Melanomas with BRAF Mutations | Melanoma Dispatch | Scoop.it

Good news for people with melanomas that have BRAF mutations — the US Food and Drug administration just greenlighted using two targeted treatments at the same time. The two targeted treatments are the BRAF inhibitor Tafinlar (dabrafenib) and the MEK inhibitor Mekinist (trametinib), and both were previously FDA-approved for separate use. Melanomas often become resistant to BRAF inhibitors, and adding the MEK inhibitor could prevent or stave off this resistance.

Cancer Commons's insight:

Reuters  |  Jan 9, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Competitors Collaborate on Melanoma Combo Treatment

Competitors Collaborate on Melanoma  Combo Treatment | Melanoma Dispatch | Scoop.it

Two pharmaceutical giants are teaming up on a phase I/II clinical trial to see if their anti-melanoma drugs work better together than on their own. The drugs are GlaxoSmithKline's Mekinist (trametinib), a U.S. Food and Drug Administration (FDA)-approved MEK inhibitor (a drug that targets MEK proteins), and Pfizer's palbociclib, an experimental inhibitor of proteins called cyclin dependent kinases. These proteins make cells divide and are abnormally active in many cancers; the FDA has fast-tracked the review of using palbociclib to treat breast cancer. In addition, GlaxoSmithKline is already testing the combination of Mekinist with dabrafenib, the company's experimental BRAF inhibitor.

Cancer Commons's insight:

Fierce Biotech│Nov 21, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Speedy Review for Melanoma Combo Treatment

The U.S. Food and Drug Administration (FDA) has granted a priority review of whether two melanoma drugs work better together. The drugs are a BRAF inhibitor called Tafinlar (dabrafenib) and a MEK inhibitor called Mekinist (trametinib); both are already FDA-approved for use separately. Tumors, however, often become resistant to BRAF inhibitors, growing back after an initial period of shrinking. The hope is that adding a MEK inhibitor will prevent this resistance. The FDA's ruling on this combination targeted treatment is expected in January 2014.

Cancer Commons's insight:

Reuters│Sep 16, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

FDA Greenlights Two New Targeted Treatments for Melanoma

FDA Greenlights Two New Targeted Treatments for Melanoma | Melanoma Dispatch | Scoop.it

Good news for people with melanomas that have spread—the U.S. Food and Drug Administration just approved two new drugs that target tumors with common mutations. The drugs are dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), an MEK inhibitor. Developed by the pharmaceutical firm GlaxoSmithKline, both drugs target BRAF V600E mutations, which occur in about half of melanoma tumors. In addition, trametinib also targets V600K mutations, which are the next most common BRAF abnormalities. While these drugs have been tested in combination, using them together is not yet approved. The FDA also okayed a new test for the BRAF V600E mutation that is made by diagnostics firm bioMerieux.

Cancer Commons's insight:

MedPage Today | May 29, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Phase III Study to Test Combining Dabrafenib and Trametinib

New Phase III Study to Test Combining Dabrafenib and Trametinib | Melanoma Dispatch | Scoop.it

Pharmaceutical firm GlaxoSmithKline has started a phase III study to see if a drug combination can prevent or delay the recurrence of melanomas with BRAF V600 mutations. Both drugs—dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor—are experimental and the study will assess the efficacy and safety of the combination. The researchers plan to enroll about 850 people from more than 200 sites worldwide in the study. Another pharmaceutical firm, Roche, is also doing late-stage trials of a different BRAF inhibitor/MEK inhibitor combination.

Cancer Commons's insight:

GlaxoSmithKline Press Release | Feb 1, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Combining Dabrafenib and Trametinib Increases Melanoma Patient Survival

People with melanoma lived longer when treated with a combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) than with dabrafenib alone, according to research in The New England Journal of Medicine. The study included 247 people with melanomas that had BRAF V600E mutations. Treatment with both drugs increased survival to 9.4 months, compared to 5.8 months with dabrafenib alone. In addition, tumors were not evident or shrank considerably in 76% of people treated with both drugs, compared to 54% of those treated with dabrafenib alone.


Primary source: http://www.nejm.org/doi/full/10.1056/NEJMoa1210093

Cancer Commons's insight:

The ASCO Post | Nov 1, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

UPDATE 1-EU Agency Backs Approval of New GlaxoSmithKline Melanoma Drug

"GlaxoSmithKline's melanoma drug Mekinist - one of several drugs being sold to Novartis under an asset swap deal - has been recommended for approval by European regulators.


"The European Medicines Agency (EMA) said on Friday its experts had backed the drug, also known as trametinib, as a treatment for unresectable or metastatic melanoma in patients with a mutation of a gene known as BRAF."

Cancer Commons's insight:

Reuters  |  Apr 25, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Treatments for Advanced Melanoma Presented at AAD

New Treatments for Advanced Melanoma Presented at AAD | Melanoma Dispatch | Scoop.it

"In recent years, the FDA has approved new drugs for the treatment of advanced melanoma, which has presented new ways to treat the disease, according to a presentation at the American Academy of Dermatology annual meeting.


“ 'In the last four years there have been four new drugs that have been FDA-approved for melanoma and what’s even more exciting is that they really speak to two new ways to treating melanoma,' Allan C. Halpern, MD, MSc, chief of dermatology service at Memorial Sloan-Kettering Cancer Center, told Healio.com.


"The most recent FDA approval, in January, was the combination of a BRAF inhibitor and a MEK inhibitor for treating advanced melanoma."

Cancer Commons's insight:

Healio  |  Mar 23, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Trial Supports Recent US FDA Approval of New Melanoma Combo Treatment

Trial Supports Recent US FDA Approval of New Melanoma Combo Treatment | Melanoma Dispatch | Scoop.it

The US Food and Drug Administration just granted accelerated approval for a treatment that combines two drugs that target melanomas with BRAF mutations — but this was contingent results of an ongoing phase III clinical trial. The drugs are the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist). Now the latest results of the trial are in and they look good. This combination treatment is not approved elsewhere in the world, and the trial included 423 people from Australia, Europe, and North and South America. Final results are expected later this year and will be presented at a scientific meeting. In addition, another trial is comparing this combination treatment to the BRAF inhibitor vemurafenib (Zelboraf), which is also FDA-approved.

Cancer Commons's insight:

GlaxoSmithKline │ Jan 24, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Targetable Genetic Abnormalities Found in Melanomas

New Targetable Genetic Abnormalities Found in Melanomas | Melanoma Dispatch | Scoop.it

More than one-third of melanomas are 'pan-negative,' meaning they lack known mutations that can be targeted for treatment. But now researchers have identified two new genetic abnormalities in pan-negative melanomas. These abnormalities consist of the BRAF gene joined with another gene (PAPSS1 or TRIM24), and so are called BRAF fusions. The new study showed that about 8% of pan-negative melanomas have BRAF fusions. Next, the researchers grew melanoma cells with these BRAF fusions in the lab and tested known targeted treatments on them. While these cultured cells were not sensitive to the BRAF inhibitor vemurafenib, they were sensitive to the MEK inhibitor trametinib, suggesting that MEK inhibitors could be used to target melanomas with these BRAF fusions.

Cancer Commons's insight:

Clinical Cancer Research │Dec 15, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Combination Treatment Extends Life in People with Melanoma

Combination Treatment Extends Life in People with Melanoma | Melanoma Dispatch | Scoop.it

Two targeted treatments that are U.S. Food and Drug Administration (FDA)-approved for melanoma may be even more effective together. The drugs are dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor. In a phase II clinical trial with 160 people, the median survival was nearly 2 years with the combination treatment compared to 20 months with dabrafenib alone. These findings were presented at the 10th International Congress of the Society for Melanoma Research in Philadelphia, Pennsylvania. Now, the dabrafenib/trametinib combo has advanced to phase III trials.

Cancer Commons's insight:

Cancer Network│Nov 20, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

FDA Asked to Approve New Combination Treatment for Melanoma

FDA Asked to Approve New Combination Treatment for Melanoma | Melanoma Dispatch | Scoop.it

Two new drugs that target melanomas were just approved by the U.S. Food and Drug Administration (FDA) in May, and the drug developer has already filed for approval to use them in combination. The drugs are dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor, and both are made by GlaxoSmithKline. The combination treatment request is based on promising results of a phase I/II trial, which showed that the two drugs work better together than dabrafenib does alone. Results of a phase III trial of the combination therapy are expected later this year.

Cancer Commons's insight:

PharmaTimes│Jul 9, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Europe Accelerates Trametinib Review

Europe Accelerates Trametinib Review | Melanoma Dispatch | Scoop.it

The European Medicines Agency has granted a speedy review of trametinib, an experimental MEK inhibitor made by pharmaceutical company GlaxoSmithKline. The firm’s application for a European license includes findings from two studies of melanomas that have BRAF V600 mutations: a phase III trial comparing trametinib to two standard chemotherapy drugs (dacarbazine and paclitaxel) and a phase I/II trial comparing trametinib alone and in combination with the experimental BRAF inhibitor dabrafenib. If approved, trametinib could be available to people with melanoma within 6 months.

Cancer Commons's insight:

GlaxoSmithKline Press Release │ Feb 7, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Researchers Write New Guide to Optimal Treatments for Melanomas with BRAF Mutations

Based on current data, researchers have developed a new treatment guide for melanomas with the most common mutations (BRAF V600). While these melanomas can be targeted with vemurafenib and dabrafenib, challenges remain. Not all tumors respond, some become resistant, and side effects can include another type of skin cancer called squamous cell carcinoma. Other treatment options include trametinib, which targets a protein called MEK, as well as immunotherapies such as high-dose interleukin 2 and ipilimumab, both of which can control tumors completely.

Cancer Commons's insight:

Lancet Oncology | Feb 1, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Trametinib Outperforms Chemotherapy for Melanomas with BRAF Mutations

A New England Journal of Medicine study reports a promising new approach to treating melanomas with BRAF mutations, which often respond to BRAF inhibitors for just a short time. Melanoma patients treated with trametinib were stable (i.e., did not get worse) for three times longer than those treated with dacarbazine, a conventional chemotherapy drug (4.8 vs. 1.5 months, respectively). Trametinib inhibits MEK, a protein that is activated by BRAF and is involved in cell division. The drug’s most common side effects were rash, diarrhea, and swelling in the legs, which could be controlled by periodically adjusting the dose.

 

Primary source: http://www.nejm.org/doi/full/10.1056/NEJMoa1203421

Cancer Commons's insight:

MedPage Today | Jun 4, 2012

more...
Shaminder Singh's curator insight, July 26, 2013 4:56 AM

Academic Journal (Other type)

Shaminder Singh's comment, July 26, 2013 5:39 AM
This is a good news for those with skin cancer. This drug can inhibit the process for longer period of time than the conventional drug.